Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
Dermata Therapeutics enrolled the first participant in a clinical trial of Tome Clearing Treatment, a once-weekly OTC acne product, which it expects to launch in H1 2027 as its second commercial product. The open-label study will enroll roughly 24 participants applying the salicylic-acid and Bioneedle treatment weekly for 12 weeks, evaluating lesion counts, IGA response, and post-inflammatory hyperpigmentation.
Key figures
- Drug Name
- Tome Clearing Treatment
- Phase Of Trial
- open-label Phase-agnostic clinical trial
- Expected launch
- H1 2027
- Planned participants
- 24
- Optional extension weeks
- 12
- Treatment duration weeks
- 12
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.